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The primary aims of this paper were (1) to evaluate the influence of intensive lifestyle weight loss and exercise intervention (ILI)
compared with diabetes support and education (DSE) upon Heart Rate Recovery (HRR) from graded exercise testing (GXT) and
(2) to determine the independent and combined effects of weight loss and fitness changes upon HRR. In 4503 participants (45–76
years) who completed 1 year of intervention, HRR was measured after a submaximal GXT to compare the influence of (ILI) with
(DSE) upon HRR. Participants assigned to ILI lost an average 8.6% of their initial weight versus 0.7% in DSE group (P < 0.001)
while mean fitness increased in ILI by 20.9% versus 5.8% in DSE (P < 0.001). At Year 1, all exercise and HRR variables in ILI
improved (P < 0.0001) versus DSE: heart rate (HR) at rest was lower (72.8± 11.4 versus 77.7± 11.7 b/min), HR range was greater
(57.7 ± 12.1 versus 53.1 ± 12.4 b/min), HR at 2 minutes was lower (89.3 ± 21.8 versus 93.0 ± 12.1 b/min), and HRR was greater
(41.25±22.0 versus 37.8±12.5 b/min). Weight loss and fitness gain produced significant separate and independent improvements
in HRR.
1. Introduction and Purpose
Type 2 diabetes (T2DM) is defined by chronic hyperglycemia
and results from combined defects in insulin secretion
and action [1]. A long-term consequence of T2DM is an
increased risk of complications leading to increased mor-
bidity and mortality from cardiovascular diseases [2]. One
of the mechanisms that contributes to this increased card-
iovascular disease risk is autonomic nervous system dys-
function, which may be associated with the metabolic
syndrome and endothelial dysfunction [3, 4]. Autonomic
nervous system dysfunction is detected by a variety of
measures including heart rate variability (HRV) at rest,
chronotropic incompetence during exercise, and impaired
recovery after exercise [5]. However, the chronic imbalance
of the autonomic nervous system, as reflected in simple heart
rate measures, is not widely recognized by clinicians as a
prevalent and potent risk factor for cardiovascular events
[3], despite abundant evidence linking it to a sedentary
lifestyle, obesity, T2DM, and cardiovascular morbidity and
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mortality. Previous concerns about emerging patterns of
increasing obesity and increasing sedentary behavior have
led to major clinical trials in Finland [6] and the United
States [7] using weight loss diet and physical activity
interventions. These early trials have demonstrated that
these interventions are successful in delaying the onset of
T2DM in individuals with glucose intolerance [8] as well
as reversal of established diabetes. However, until the Look
AHEAD (Action for Health in Diabetes) Trial [9], no large-
scale multicenter randomized clinical trials have examined
the longitudinal influence of behavioral intervention upon
HRR and autonomic dysfunction using diet and exercise
interventions in overweight/obese individuals with T2DM.
The primary aims of this paper were (1) to examine the
influence of one year of an intensive weight loss diet and
exercise intervention (ILI) upon autonomic dysfunction as
measured by Heart Rate Recovery (HRR) from exercise stress
testing and (2) to evaluate the separate and combined effects
of weight loss and fitness changes.
2. Methods
2.1. Subjects. A detailed description of the baseline charac-
teristics of Look AHEAD participants has been published
elsewhere [10]. Data from 4,503 individuals who completed
the assessment of fitness by treadmill testing at baseline
and 1 year were available. At baseline, all participants were
diagnosed with T2DM with mean duration of diabetes
of 6.7 ± 4.5 years, and HbA1c level of 7.3 ± 1.2% were
58.7 ± 6.8 years old with a BMI or 35.8 ± 5.8 kg/m2and
received general medical care and treatment for their diabetes
from their personal healthcare provider. While participants
with and without β-blocker use were combined for initial
analyses, subsequent separate analyses were conducted on
those participants (N = 3371) not on β-blocker medication
due to the known influence of β-blockers on all heart rate
variables.
2.2. Intervention
2.2.1. Intensive Lifestyle Intervention Group (ILI). Specific
details of the lifestyle intervention used in the Look AHEAD
Study have been published previously [11]. Briefly, for
months 1–6, participants attended weekly on-site treatment
sessions that included three group sessions and one individ-
ual meeting with their Lifestyle Counselor each month. Dur-
ing months 7–12, participants attended two group meetings
and one individual session per month and one motivational
campaign to promote adherence to the recommended weight
loss behaviors. The 1-year weight loss goal for individual
participants was 10% of their body weight.
2.2.2. Diabetes Support and Education Intervention Group
(DSE). The DSE group has previously been described [11].
Individuals randomly assigned to DSE received general
recommendations related to healthful eating and physical
activity, and safety recommendations for an individual with
type 2 diabetes. Participants attended an initial diabetes
education session and were invited to attend 3 additional
group sessions, that addressed topics related to diet, physical
activity, and social support but were not provided individual
strategies to change diet or physical activity.
2.3. Assessments. Though Look AHEAD assessment method
have been published in detail [11, 12], selected methods
relevant to the present paper are presented below.
2.3.1. Cardiorespiratory Fitness. A graded exercise treadmill
test was used to assess cardiorespiratory fitness at baseline
and at 1 year. The speed of the treadmill was set at 1.5,
2.0, 2.5, 3.0, 3.5, or 4.0mph for the baseline test based on
the participant’s preferred walking speed and their heart
rate response during the first minute of the test; this speed
remained constant throughout the test. The grade of the
treadmill was initially set at 0% and increased by 1% at 1-
minute intervals throughout the test. Heart rate was assessed
at rest, during the last 10 seconds of each exercise stage,
and at the point of test termination using a 12-lead ECG.
Rating of perceived exertion (RPE) was assessed using the
Borg 15-category scale (range is on a scale from 6–20) during
the last 15 seconds of each stage and at the point of test
termination. Blood pressure was assessed using a manual
sphygmomanometer and stethoscope during the last 45
seconds of each even minute stage (e.g., 2min, 4min, etc.).
Baseline Test. The baseline test was terminated at the point
of volitional exhaustion or at the point where ACSM [13]
test termination criteria were observed, that is, serious
arrhythmias, angina, and signs of myocardial ischemia, and
so forth. A baseline test was considered valid if the maximal
heart rate was ≥85% of age-predicted maximal heart rate
(HRMax = 220 minus age) if the participant was not taking
a β-blocking medication. If the participant was taking a β-
blocker medication, the baseline test was considered valid
if RPE was ≥18 at the point of termination. In addition, to
be eligible, all participants needed to achieve ≥4 metabolic
equivalents (METs) on the baseline graded exercise test,
where 1MET is equal to 3.5mL/kg/min of oxygen uptake.
1-Year Test. This test was a submaximal test [14]. It was per-
formed at the same walking speed as the baseline test and was
terminated at the time when the participant first achieved or
exceeded 80% of age-predictedmaximal heart rate (HRMax =
220 minus age), if the participant was not taking a β-blocker
at either the baseline or 1-year assessment period. If the
participant was taking a β-blocker at either the baseline or
1-year assessment, then the submaximal test was terminated
at the point when the participant first reported achieving or
exceeding a rating of 16 on the 20 point RPE scale, that is,
80% of RPE = 20. Cardiorespiratory fitness was defined as
the estimated metabolic equivalent (MET) level based on the
treadmill work load (i.e., speed and grade) [13] using either
the criteria of attaining 80% of maximal heart rate or an RPE
of ≥16 for those on a β-blocker. Data from 4503 individuals
who completed the assessment of fitness at baseline and 1
year were available.
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Heart Rate Recovery (HRR). Heart Rate Recovery is a mea-
surement of how much the heart rate falls during the first
few minutes after peak exercise, that is, the ability of the
heart to return itself to a resting state after being elevated
during exercise [15]. Normal heart rate recovery is defined
as a decrease in pulse of 15 to 25 beats per minute. Abnormal
heart rate recovery is defined as a decrease in pulse of 12 or
fewer beats per minute. Heart rate was recorded immediately
after exercise and every 2 minutes. For the purpose of this
analysis, Heart Rate Recovery (HRR) is defined as HRR =HR
at peak-HR at 2 minutes.
2.3.2. Statistical Analysis. Analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC). Normality of the
outcome variable, Heart Rate Recovery (HRR) at Year 1, was
examined prior to the fit of multiple linear regression mod-
els. Spearman’s correlation coefficients were used to assess
the bivariate associations between the outcome variable and
continuous measures at baseline as well as 1-year changes
in weight and fitness. The analysis of variance (ANOVA)
approach was used to examine bivariate associations between
the outcome and categorical variables such as treatment
group, gender, diabetes medication usage, CVD history,
and hypertension. Multivariate analyses were conducted,
examining the separate and combined effects of weight
loss and fitness change on HRR at Year 1. Variables that
were significantly associated with the outcome in bivariate
analyses were entered into two separate multiple linear
regression models: one for assessing the treatment group
effect on year 1 HRR after adjusting for baseline covariates;
the other for assessing the combined effect of weight loss and
fitness change using a derived categorical variable with five
levels. Least square means and standard errors were obtained
from these two models along with pairwise P values for
comparing ILI and DES or pairs of two LSMEANs of the five
categories; the type I error rate was fixed at 0.05.
3. Results
3.1. Baseline Characteristics. At baseline, none of the demo-
graphic variables were significantly different when com-
paring ILI with DSE and these demographics have been
published previously [10] on a larger sample (n = 5145);
however, the data for this paper are only on those for
whom we could calculate HRR at Year 1 (n = 4503). The
reasons for missing data have been explained in an earlier
report by Jakicic et al. [14]. These included scheduling issues,
refusal to participate, medical reasons, and other reasons not
specified.
3.2. Heart Rate Recovery Variables at Baseline and Year 1.
The data at baseline and at Year 1 are presented for the
heart rate variables in Table 1. Separate analyses were done
for those with and without β-blocker usage. At baseline,
none of the heart rate variables were significantly different
between ILI versus DSE; this was true for both those with and
without β-blocker usage. As expected, all resting, exercise,
and recovery heart rate variables were lower for those on β-
blockers and therefore subsequent bivariate and multivariate
analyses were done only on those individuals who were not
on β-blocker since the groups could not be combined in
further HRR analyses.
At the Year 1 fitness assessment, which used a submax-
imal test [14], all heart rate variables improved more (P <
0.0001) in ILI versus DSE (Table 1), that is, resting heart
rate was lower (72.8 ± 11.4 versus 77.7 ± 11.7 b/min), heart
rate range increased (57.7 ± 12.1 versus 53.1 ± 12.4 b/min),
heart rate at 2 minutes of recovery was lower (89.3 ± 21.8
versus 93.0±12.1 b/min), and heart rate recovery was greater
(41.25 ± 22.0 versus 37.8 ± 12.5 b/min) for ILI versus DSE,
respectively. Nevertheless, ILI and DSE reached the same
peak heart rate (130.5 ± 6.2 versus 130.8 ± 6.6 b/min for
ILI versus DSE, resp.) confirming that both groups exercised
to the same peak level during the exercise test. A similar
trend was observed at Year 1 for those on β-blockers with
ILI exhibiting greater improvement in all heart rate variables
yet still reaching the same peak heart rate during exercise.
3.3. Correlates of Heart Rate Recovery at Year 1. Table 2
lists the Spearman correlation coefficients of 1-year Heart
Rate Recovery with selected baseline measures, including
age, duration of diabetes, waist circumference, BMI, HbA1c,
and Triglycerides, and 1-year changes in weight and fitness.
In this analysis, only those participants without β-blocker
usage were included, and we used this analysis to determine
which variables to include in the model used in Table 4.
Not surprisingly, age was the strongest predictor of HRR
(r = −0.22; P < .0001) since the key heart rate variables
influencing the HRR also are lower with greater age, that
is, lower peak HR with exercise and slower recovery after
exercise with greater age. The second strongest predictor
of faster HRR was the percentage of weight change (r =
−0.18; P < .0001). Other variables that were associated with
HRR were self-reported duration of diabetes (r = −0.11;
P < .0001); hemoglobin A1c (r = −0.10; P < .0001);
waist circumference (r = −0.10; P < .0001); percent fitness
change (r = −0.09; P < .0001).
Once these HRR predictor variables were identified, all
participants (ILI and DSE) were divided into groups based
upon (1) treatment group (Table 3(a)); (2) age, gender,
diabetes medication usage, CVD history, hypertension, waist
circumference (Table 3(b)); and (3) weight losses and/or
fitness gains (Table 3(c)). In every comparison, significant,
or borderline significant relationships were demonstrated.
3.4. Influence of Weight Change and Fitness Change Gain
upon Heart Rate Recovery at Year 1. Based on their one-
year weight loss and fitness changes, participants who were
not on a β-blocker were divided into four separate weight
loss groups and four separate fitness gain groups, revealing
that HRR improved with greater weight losses as well as
with greater fitness gains (Table 3(c)). Next, to examine
the combined influences of weight loss and fitness gain on
HRR, the participants were divided into 16 paired subgroups,
based upon their combined weight and fitness losses and
or gains (pairings noted in footnote in Table 3(c)). These
groupings were used to form five separate groups, ranging
from “Low” success in which participants either gained
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Table 2: Correlations with Year 1 heart rate recoverya.
Variable N Spearman correlation P value
Age 3371 −0.2220 <.0001
Self-reported duration of diabetes (yrs) 3348 −0.1018 <.0001
Waist circumference 3367 −0.0999 <.0001
BMI 3371 −0.0464 0.0071
Hemoglobin A1c% 3371 −0.1026 <.0001
Triglycerides (mgdL) 3371 −0.0863 <.0001
Percent weight change 3371 −0.1837 <.0001
Percent fitness change 3289 0.0849 <.0001
a
Results at Year 1 for 3371 participants never on β-blocker, where HRR could be calculated.
weight, lost fitness, or both to “High” success in which the
participants achieved a 10% weight loss and 15% fitness gain
at Year 1. This combined fitness/weight loss variable was
significantly related to HRR at Year 1 and is illustrated in
Figure 1, where there is a marked improvement in those in
the “High Success” group compared to all other groups with
lesser weight loss and/or fitness gain.
3.5. Multiple Regression Analysis for Heart Rate Recovery at
Year 1. As a consequence of the intervention, ILI achieved a
greater HRR than did DSE at Year 1 (Figure 1). Even
after adjusting for significant influencing variables (i.e., age,
gender, duration of diabetes, HbA1c, BMI, waist circum-
ference, etc.), the treatment group effect remained highly
significant. Results for the multiple linear regression models
are presented in Table 4(a). The least square means for HRR
were 41.48 for the ILI and 37.94 for the DSE, resulting in
a highly significant between group difference (P < .0001)
(Figure 1). A separate multiple linear regression model was
fit to examine the differences in HRR among the five success
groups (low, moderate low, moderate, moderate high, and
high success). (Table 4(b)). The least square means for HRR
were 44.92, and 40.60 for the high and moderate high
success groups, and 38.64, 38.34, and 37.79 for the moderate,
moderate low, and low success groups, respectively. Adjusted
pairwise group comparisons revealed that HRR for the high
success and moderate high success groups were significantly
higher than all lower success groups (P < .05). Themoderate,
moderate low, and low groups were not significantly different
from each other.
4. Discussion
The key findings are that an intensive lifestyle program of
weight loss through diet and exercise resulted in greater
improvement in HRR than a diabetes support education
program at one year (P < 0.001) and furthermore, the
magnitude of the improvement was influenced by the
combined effects of weight loss and fitness gain. Though
some studies have evaluated the effects of weight loss and/or
physical activity onHRR in overweight and obese individuals
and also those with T2DM, to our knowledge, the Look
AHEAD trial is the first study to examine the effects of
an extended (1 year) intensive lifestyle intervention upon
HRR: weight loss/fitness gains and DSE versus ILI
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Figure 1: Combined influence of weight loss and fitness gain on
Heart Rate Recovery (left) and Comparison of DSE versus ILI
(right). (Levels of success were determined by combinations of
weight loss and fitness gain in the 8 subgroups as described in
Table 3(c)).
HRR in a large cohort of overweight and obese individuals
with type 2 DM.
4.1. Baseline Characteristics and 1 Year Changes with Interven-
tion in Look AHEAD. The characteristics of the individuals
randomized to ILI and DSE were essentially equal at baseline
and none were found to be statistically different. While
it was not the aim of this paper to analyze all of the
changes in these variables after 1 year of intervention in
the Look AHEAD study group, another publication [10]
has reported greater benefits for weight loss (8.6 versus
0.7%; P < 0.0001), fitness gain (20.9 versus 5.7%; P <
0.0001), and lowered hemoglobin A1c (7.3 to 6.6% versus
7.3 to 7.2%) in ILI versus DSE, respectively. Systolic and
diastolic pressure, triglycerides, HDL cholesterol, and urine
albumin-to-creatinine ratio improved more in ILI than
DSE participants (all P < 0.01) and the prevalence of
the metabolic syndrome declined from 93.6 to 78.9% in the
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Table 3: HRR according to treatment, select variables, weight loss, fitness gain, and combined effects of weight loss/fitness gain.
(a) Influence of treatment upon HRR at Year 1
Variable Subgroup N Mean ± SD P value
Treatment
Diabetes support and education 1665 37.92± 12.42
<.0001
Weight loss intervention 1706 41.59± 12.41
(b) Influence of select variables upon HRR at Year 1
Variable Subgroup N Mean ± SD P value
Age
45–55 1239 42.26± 12.47
<.000156–65 1723 39.15± 12.21
66–76 409 34.88± 12.45
Gender
Male 1310 39.26± 12.17
0.0540
Female 2061 40.11± 12.77
Diabetes severity
No diabetic meds, no insulin 435 42.36± 12.68
<.0001Diabetic meds only 2290 39.73± 12.43
Insulin only 128 37.54± 12.74
Insulin and diabetic meds 469 38.17± 12.52
History of CVD
No 3124 39.92± 12.60
0.0160
Yes 247 37.93± 11.75
Hypertension
No 729 42.72± 12.53
<0.0001
Yes 2642 38.97± 12.43
Waist circumference group
(adjusted for gender)
1 676 41.71± 12.72
0.0062
2 695 40.01± 12.24
3 799 39.61± 12.56
4 516 38.51± 12.13
5 681 38.73± 12.76
(c) Influence of weight losses and fitness gains upon HRR at Year 1
Variable Subgroup N Mean ± SD P value
Weight group
Weight gain (1)∗ 839 37.69± 12.48
<.00014.9% weight loss to 0% weight gain (2) 1154 38.36± 11.88
5% weight loss to 9.9% weight loss (3) 706 40.21± 12.28
10% weight loss and greater (4) 741 43.92± 12.88
Fitness group
Fitness loss (5) 764 38.98± 12.82
0.00010% to 7.49% fitness gain (6) 781 39.96± 12.48
7.5% fitness gain to 14.9% fitness gain (7) 526 40.25± 12.06
15% fitness gain and greater (8) 1284 40.78± 12.49
Combined weight and fitness
group∗
Low success 818 38.11± 12.57
<0.0001
Moderate low success 537 38.68± 12.60
Moderate success 595 38.62± 11.71
Moderate high success 925 40.61± 12.31
High success 480 44.29± 12.72
∗
Groupings: The five combined weight and fitness groups were determined by combining the four weight groups with the 4 fitness groups, based upon
relatives success in both weight loss and fitness gain. Low success (1 and 5; 2 and 5; 1 and 6); moderate low success (3 and 5; 1 and 7; 2 and 6); moderate
success (3 and 6; 2 and 7; 4 and 5; 1 and 8); moderate high success (2 and 8; 4 and 6; 4 and 7; 3 and 6; 3 and 8); high success (4 and 8).
ILI group compared with a decline of 94.4 to 87.3% in the
DSE group.
4.2. Heart Rate Recovery and β-blocker Usage. In response to
the intervention, ILI participants exhibited improved HRR
compared with DSE. This was true in those participants
without β-blocker usage as well as those taking β-blockers
(Tables 1(a) and 1(b)). This latter finding is consistent with
the results of Maeder et al. [16] who found that β-blocker
use did not influence the interpretation of HRR despite the
lower absolute values due to the β-blocker effect. Two other
studies have found similar results. Arena et al. [17] studied
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Table 4: (a) Association of Year 1 Heart Rate Recovery with treatment group. (b) Association of Year 1 Heart Rate Recovery with combined
weight and fitness changes.
(a)
HRR at Year 1
Model∗ B SE P value R2
Model A
ILI versus DSE 3.544 0.379 <0.0001 0.255
Least square means
LSMEAN SE P value for testing equality of LSMEANs
ILI 41.48 0.27
<0.0001 (ILI versus DSE)
DSE 37.94 0.27
(b)
HRR at Year 1
Model∗ B SE P value R2
Model B
Moderate high success versus high success −4.32 0.62 <0.0001
0.27
Moderate success versus high success −6.28 0.68 <0.0001
Moderate low success versus high success −6.58 0.70 <0.0001
Low success versus high success −7.13 0.64 <0.0001
Least square means∧
LSMEAN SE
Low successa 37.79 0.39
Moderate low successb 38.34 0.48
Moderate successc 38.64 0.45
Moderate high successa,b,c,d 40.60 0.36
High successa,b,c,d 44.92 0.51
∧
Same superscripts indicate groups are significantly different from each other.
∗Models were adjusted for baseline covariates, including age, gender, clinical site, diabetes duration, diabetes medication use, history of cardiovascular
disease, hypertension, BMI, waist circumference, HbA1c, and triglycerides.
520 individuals with heart failure (HF) and found that
HRR maintains its prognostic value in HR irrespective of
β-blocker use. Karnik et al. [18] conducted a retrospec-
tive study of 334 patients who underwent exercise stress
echocardiography and compared those with and without β-
blocker therapy. They found that HRR was not affected by
β-blocker use in patients without stress-induced ECG abnor-
malities; however, in those with a positive stress echocar-
diogram result, HRR improved in the presence of β-blocker
therapy.
During exercise, there is an increase in heart rate due to
increased sympathetic and reduced vagal (parasympathetic)
activity. However, when the exercise bout is stopped, the
rapid decrease in heart rate is predominantly accomplished
by vagal reactivation, making HRR a marker of parasym-
pathetic control of the heart. Therefore, a delay in HRR
after exercise is an indicator of impaired autonomic nervous
system functioning, specifically reduced parasympathetic
activity. These results suggest that the ILI intervention, which
produced weight loss and improved physical fitness, also had
a beneficial effect upon autonomic nervous system function
as reflected in the improved HRR.
4.3. Relationship of Weight Loss and Fitness Gain on HRR. We
found that both greater weight loss and fitness gains were
associated with greater improvements in HRR (P < 0.001).
While there is a paucity of published work that addresses the
issue of whether weight loss influences HRR, a recent study
by Brinkworth et al. [19] measured HRR in 42 overweight
and obese males (body mass index 33.8 ± 0.6 kg/m2, mean
age 46.5 + 1.3 years) before and after a 12-week weight
loss program based upon an energy restricted diet while
physical activity was kept at baseline level. These individuals
had neither T2DM nor symptoms of cardiovascular disease,
but rather had components of the metabolic syndrome.
Although peak heart rate remained unchanged, HRR at 1
minute improved significantly from 33.1 + 1.4 to 36.9 +
1.3 beats/min (P < .001) after weight loss. There was
neither a change in physical activity levels (P = .67) nor
cardiorespiratory fitness (P = .30) and thus these benefits
were attributed directly to the weight loss.
In 373 postmenopausal women, similar in age (45–75 y)
and ethnic diversity to our population, Earnest et al. [20]
studied autonomic nervous system balance as measured by
heart rate variability (HRV) after a six-month moderate
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exercise training program in which participants exercised at
50%, 100%, and 150% of the NIH Consensus Development
Panel’s recommended minimal physical activity level [21].
They found significant (P < 0.0001) improvement in all
parasympathetically derived time and frequency domain
measurements associated with HRV in a dose-dependent
pattern across all groups, with only the 100% and 150%
groups experiencing improvements in HRV, revealing that
moderate intensity exercise is sufficient to improve auto-
nomic nervous system function as measured by HRV.
When we examined the combined groups of weight loss
and fitness gain in our participants, we found a combined
influence. The group that achieved the highest success, a
10% weight loss and a 15% fitness gain at the end of
Year 1 achieved the greatest improvement in HRR. Overall,
the present data support a dose-response relationship such
that those participants that met more of the goals, as
we rated from “Low” to “High” success, attained greater
improvements in HRR. Thus, it seems important that
clinicians encourage both weight loss and exercise in the
treatment of overweight/obese and sedentary patients with
diabetes.
4.4. Heart Rate Recovery, Autonomic Dysfunction, and T2DM.
Heart Rate Recovery (HRR) appears to be an established
prognostic indicator for cardiovascular disease and all-cause
mortality in healthy individuals as well as those with T2DM.
Cheng et al. [15] examined the association of HRR to
CVD-related and all-cause mortality in 2,333 men with
documented diabetes (mean age 49.4 years) that had baseline
HRR measurement following maximal exercise; however,
HRR was measured as heart rate peak—heart rate at 5min
of recovery. During a median of 14.9 years followup, men
in the highest quartile of HRR (i.e., healthiest group), had
fewer cardiovascular deaths compared with those in the other
quartiles illustrating that a decreased HRR, even measured as
long as 5min after recovery, was independently predictive of
cardiovascular and all-cause death in men with T2DM.
Carnethon et al. [22] measured heart rate variability
(HRV) and QT duration at baseline and annually over
3.2 years in 2,980 participants in the Diabetes Prevention
Program (DPP). HRV and QT duration reflect fitness and
autonomic nervous system function; DPP was a randomized
clinical trial using lifestyle intervention in adults at risk
for diabetes development. They found that higher rest-
ing heart rate at baseline, representing both poor fitness
and impaired autonomic function, was associated with a
modestly increased incidence of diabetes. Further, improved
fitness and/or autonomic function, as indicated by lowered
heart rate and increased HRV, was associated with a reduced
risk of development of diabetes, even after adjustment for
changes in weight and physical activity levels.
Yamada et al. [23] examined the relationship between
silent myocardial ischemia (SMI) and HRR in type 2 diabetes
and found that HRR was significantly associated with SMI
(odds ratio 0.83 [95% CI 0.75–0.92]; P = 0.0006), even after
adjustment formaximal exercise workload, resting heart rate,
maximum heart rate, rate pressure product, HbA1c, use of
sulfonamides, and a history of cardiovascular disease, leading
the investigators to conclude that HRR can predict SMI in
patients with type 2 diabetes.
4.5. Long-Term Impact of the Look AHEAD Study on Cardio-
vascular Outcomes. The Look AHEAD (Action for Health
in Diabetes) study is designed to assess the long-term
health consequences of intentional weight loss in individuals
with type 2 diabetes [11]. The primary outcomes, which
are CVD morbidity and mortality parameters. These data
are now being analyzed and have not yet been reported.
However, the present study shows that HRR, an important
surrogate marker of CVD, can be improved with greater
weight loss and gains in fitness. This observation is supported
by a recent study by Georgoulias et al. [24] in which 285
patients underwent SPECT myocardial perfusion imaging
combined with exercise testing. Cardiovascular death and
nonfatal myocardial infarction were considered as hard
cardiac events, while late revascularization procedures as soft
events. During the mean follow-up period of 31 months,
hard cardiac events occurred in 21 (8%) patients, 15 of
whom had abnormal HRR value, while 35 (14%) patients
underwent revascularization, 31 of whom had abnormal
HRR values. HRR was a strong predictor for both hard
cardiac (coefficient = −0.41, SE = 0.052, P < 0.001) and
soft cardiac events (coefficient = −0.63, SE = 0.058, P <
0.001). Thus, the change inHRR variable herein is a favorable
outcome and suggests a reduction in CVD risk.
5. Conclusions
A lifestyle intervention to promote weight loss through
diet and physical activity improved Heart Rate Recovery
following exercise, a variable associated with autonomic dys-
function and cardiovascular risk in adults with T2DM.While
weight loss and fitness gains each have separate beneficial
influences on HRR, those participants who achieved both
the greatest amount of weight loss and the greatest gains in
fitness showed the most amount of improvement in Heart
Rate Recovery, an important marker of cardiovascular risk.
Appendix
A. Look AHEAD Research Group at Year 1
A.1. Clinical Sites
The Johns Hopkins Medical Institutions. Frederick L. Bran-
cati, M.D., MHS (principal investigator); Jeff Honas, MS
(program coordinator); Lawrence Cheskin, M.D. (coinves-
tigator); Jeanne M. Clark, M.D., MPH (coinvestigator);
Kerry Stewart, EdD (coinvestigator); Richard Rubin, Ph.D.
(coinvestigator); Jeanne Charleston, RN; Kathy Horak, RD.
Pennington Biomedical Research Center. George A. Bray,
M.D. (principal investigator); Kristi Rau (program co-
ordinator); Allison Strate, RN (program coordinator);
Brandi Armand, LPN (program coordinator); Frank L.
Greenway, M.D. (coinvestigator); Donna H. Ryan, M.D.
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(coinvestigator); Donald Williamson, Ph.D. (coinvestigator);
Amy Bachand; Michelle Begnaud; Betsy Berhard; Elizabeth
Caderette; Barbara Cerniauskas; David Creel; Diane Crow;
Helen Guay; Nancy Kora; Kelly LaFleur; Kim Landry; Missy
Lingle; Jennifer Perault; Mandy Shipp, RD; Marisa Smith;
Elizabeth Tucker.
The University of Alabama at Birmingham. Cora E. Lewis,
M.D., MSPH (principal investigator); Sheikilya Thomas
MPH (program coordinator); Monika Safford, M.D. (coin-
vestigator); Vicki DiLillo, Ph.D.; Charlotte Bragg, MS, RD,
LD; Amy Dobelstein; Stacey Gilbert, MPH; Stephen Glasser,
M.D.; Sara Hannum, MA; Anne Hubbell, MS; Jennifer Jones,
MA; DeLavallade Lee; Ruth Luketic, MA, MBA, MPH; Karen
Marshall; L. Christie Oden; Janet Raines, MS; Cathy Roche,
RN, BSN; Janet Truman; Nita Webb, MA; Audrey Wrenn,
MAEd.
Harvard Center. Massachusetts General Hospital. David M.
Nathan, M.D. (principal investigator); Heather Turgeon, RN,
BS, CDE (program coordinator); Kristina Schumann, B.A.
(program coordinator); Enrico Cagliero, M.D. (coinvesti-
gator); Linda Delahanty, MS, RD (coinvestigator); Kathryn
Hayward, M.D. (coinvestigator); Ellen Anderson, MS, RD
(coinvestigator); Laurie Bissett, MS, RD; Richard Ginsburg,
Ph.D.; Valerie Goldman, MS, RD; Virginia Harlan, MSW;
Charles McKitrick, RN, BSN, CDE; Alan McNamara, BS;
Theresa Michel, DPT, DSc CCS; Alexi Poulos, B.A.; Barbara
Steiner, EdM; Joclyn Tosch, B.A.
Joslin Diabetes Center. Edward S. Horton,M.D. (principal
investigator); Sharon D. Jackson, MS, RD, CDE (program
coordinator); Osama HaM.D.y, M.D., Ph.D. (coinvestigator);
A. Enrique Caballero, M.D. (coinvestigator); Sarah Bain,
BS; Elizabeth Bovaird, BSN, RN; Ann Goebel-Fabbri, Ph.D.;
Lori Lambert, MS, RD; Sarah Ledbury, MEd, RD; Maureen
Malloy, BS; Kerry Ovalle, MS, RCEP, CDE.
Beth Israel Deaconess Medical Center. George Blackburn,
M.D., Ph.D. (principal investigator); Christos Mantzoros,
M.D., DSc (coinvestigator); Kristinia Day, RD; Ann McNa-
mara, RN.
University of Colorado Health Sciences Center. James O. Hill,
Ph.D. (principal investigator); Marsha Miller, MS, RD (pro-
gram coordinator); JoAnn Phillipp, MS (program coordi-
nator); Robert Schwartz, M.D. (coinvestigator); Brent Van
Dorsten, Ph.D. (coinvestigator); Judith Regensteiner, Ph.D.
(coinvestigator); Salma Benchekroun MS; Ligia Coelho, BS;
Paulette Cohrs, RN, BSN; Elizabeth Daeninck, MS, RD; Amy
Fields, MPH; Susan Green; April Hamilton, BS, CCRC; Jere
Hamilton, B.A.; Eugene Leshchinskiy; Michael McDermott,
M.D.; Lindsey Munkwitz, BS; Loretta Rome, TRS; Kristin
Wallace, MPH; Terra Worley, B.A.
Baylor College of Medicine. John P. Foreyt, Ph.D. (principal
investigator); Rebecca S. Reeves, DrPH, RD (program
coordinator); Henry Pownall, Ph.D. (coinvestigator); Ashok
Balasubramanyam, MBBS (coinvestigator); Peter Jones,
M.D. (coinvestigator); Michele Burrington, RD; Chu-Huang
Chen,M.D., Ph.D. (coinvestigator); Allyson Clark, RD;Molly
Gee, MEd, RD; Sharon Griggs; Michelle Hamilton; Veronica
Holley; Jayne Joseph, RD; Patricia Pace, RD: Julieta Palencia,
RN; Olga Satterwhite, RD; Jennifer Schmidt; Devin Volding,
LMSW; Carolyn White.
University of California at Los Angeles School of Medicine.
Mohammed F. Saad, M.D. (principal investigator); Siran
Ghazarian Sengardi, M.D. (program coordinator); Ken C.
Chiu, M.D. (coinvestigator); Medhat Botrous; Michelle
Chan, BS; Kati Konersman, MA, RD, CDE; Magpuri Per-
petua, RD.
The University of Tennessee Health Science Center
University of Tennessee East. Karen C. Johnson, M.D., MPH
(principal investigator); Carolyn Gresham, RN (program
coordinator); Stephanie Connelly, M.D., MPH (coinvestiga-
tor); Amy Brewer, RD, MS; Mace Coday, Ph.D.; Lisa Jones,
RN; Lynne Lichtermann, RN, BSN; Shirley Vosburg, RD,
MPH; and J. Lee Taylor, MEd, MBA.
University of Tennessee Downtown. Abbas E. Kitabchi,
Ph.D., M.D. (principal investigator); Helen Lambeth, RN,
BSN (program coordinator); Debra Clark, LPN; Andrea
Crisler, MT; Gracie Cunningham; Donna Green, RN; Debra
Force, MS, RD, LDN; Robert Kores, Ph.D.; Renate Rosenthal
Ph.D.; Elizabeth Smith, MS, RD, LDN; and Maria Sun, MS,
RD, LDN; and Judith Soberman, M.D. (coinvestigator).
University of Minnesota. Robert W. Jeffery, Ph.D. (principal
investigator); Carolyn Thorson, CCRP (program coordi-
nator); John P. Bantle, M.D. (coinvestigator); J. Bruce
Redmon, M.D. (coinvestigator); Richard S. Crow, M.D.
(coinvestigator); Scott Crow, M.D. (coinvestigator); Susan
K Raatz, Ph.D., RD (coinvestigator); Kerrin Brelje, MPH,
RD; Carolyne Campbell; Jeanne Carls, MEd; Tara Carmean-
Mihm, B.A.; Emily Finch, MA; Anna Fox, MA; Elizabeth
Hoelscher, MPH, RD, CHES; La Donna James; Vicki A.
Maddy, BS, RD; Therese Ockenden, RN; Birgitta I. Rice, MS,
RPh CHES; Tricia Skarphol, BS; Ann D. Tucker, B.A.; Mary
Susan Voeller, B.A.; Cara Walcheck, BS, RD.
St. Luke’s Roosevelt Hospital Center. Xavier Pi-Sunyer, M.D.
(principal investigator); Jennifer Patricio, MS (program
coordinator); Stanley Heshka, Ph.D. (coinvestigator); Car-
men Pal, M.D. (coinvestigator); Lynn Allen, M.D.; Diane
Hirsch, RNC, MS, CDE; Mary Anne Holowaty, MS, CN.
University of Pennsylvania. Thomas A.Wadden, Ph.D. (prin-
cipal investigator); Barbara J. Maschak-Carey, MSN, CDE
(program coordinator); Stanley Schwartz, M.D. (coinves-
tigator); Gary D. Foster, Ph.D. (coinvestigator); Robert I.
Berkowitz, M.D. (coinvestigator); Henry Glick, Ph.D. (coin-
vestigator); Shiriki K. Kumanyika, Ph.D., RD,MPH (coinves-
tigator); Johanna Brock; Helen Chomentowski; Vicki Clark;
Canice Crerand, Ph.D.; Renee Davenport; Andrea Diamond,
MS, RD; Anthony Fabricatore, Ph.D.; Louise Hesson, MSN;
Stephanie Krauthamer-Ewing, MPH; Robert Kuehnel, Ph.D.;
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Patricia Lipschutz, MSN; Monica Mullen, MS, RD; Leslie
Womble, Ph.D., MS; Nayyar Iqbal, M.D.
University of Pittsburgh. David E. Kelley, M.D. (principal
investigator); Jacqueline Wesche-Thobaben, RN, BSN, CDE
(program coordinator); Lewis Kuller, M.D., DrPH (coinves-
tigator); Andrea Kriska, Ph.D. (coinvestigator); Janet Bonk,
RN, MPH; Rebecca Danchenko, BS; Daniel Edmundow-
icz, M.D. (coinvestigator); Mary L. Klem, Ph.D., MLIS
(coinvestigator); Monica E. Yamamoto, DrPH, RD, FADA
(coinvestigator); Barb Elnyczky, MA; George A. Grove, MS;
Pat Harper, MS, RD, LDN; Janet Krulia, RN,BSN,CDE; Juliet
Mancino, MS, RD, CDE, LDN; Anne Mathews, MS, RD,
LDN; Tracey Y. Murray, BS; Joan R. Ritchea; Jennifer Rush,
MPH; Karen Vujevich, RN-BC, MSN, CRNP; Donna Wolf,
MS.
The Miriam Hospital/Brown Medical School. Rena R. Wing,
Ph.D. (principal investigator); Renee Bright, MS (program
coordinator); Vincent Pera, M.D. (coinvestigator); John
Jakicic, Ph.D. (coinvestigator); Deborah Tate, Ph.D. (coinves-
tigator); Amy Gorin, Ph.D. (coinvestigator); Kara Gallagher,
Ph.D. (coinvestigator); Amy Bach, Ph.D.; Barbara Bancroft,
RN, MS; Anna Bertorelli, MBA, RD; Richard Carey, BS;
Tatum Charron, BS; Heather Chenot, MS; Kimberley Chula-
Maguire, MS; Pamela Coward, MS, RD; Lisa Cronkite, BS;
Julie Currin, M.D.; Maureen Daly, RN; Caitlin Egan, MS;
Erica Ferguson, BS, RD; Linda Foss, MPH; Jennifer Gauvin,
BS; Don Kieffer, Ph.D.; Lauren Lessard, BS; Deborah Maier,
MS; JP Massaro, BS; Tammy Monk, MS; Rob Nicholson,
Ph.D.; Erin Patterson, BS; Suzanne Phelan, Ph.D.; Hollie
Raynor, Ph.D., RD; Douglas Raynor, Ph.D.; Natalie Robin-
son, MS, RD; Deborah Robles; Jane Tavares, BS.
The University of Texas Health Science Center at San Antonio.
Steven M. Haffner, M.D. (principal investigator); Maria G.
Montez, RN, MSHP, CDE (program coordinator); Carlos
Lorenzo, M.D. (coinvestigator).
University ofWashington/VA Puget SoundHealth Care System.
Steven Kahn MB, ChB (principal investigator); Brenda
Montgomery, RN, MS, CDE (program coordinator); Robert
Knopp, M.D. (coinvestigator); Edward Lipkin, M.D. (coin-
vestigator); Matthew L. Maciejewski, Ph.D. (coinvestigator);
Dace Trence, M.D. (coinvestigator); Terry Barrett, BS; Joli
Bartell, B.A.; Diane Greenberg, Ph.D.; Anne Murillo, BS;
Betty Ann Richmond, MEd; April Thomas, MPH, RD.
Southwestern American Indian Center, Phoenix, Arizona and
Shiprock, New Mexico. William C. Knowler, M.D., DrPH
(principal investigator); Paula Bolin, RN, MC (program
coordinator); Tina Killean, BS (program coordinator); Cathy
Manus, LPN (coinvestigator); Jonathan Krakoff, M.D. (coin-
vestigator); Jeffrey M. Curtis, M.D., MPH (coinvestigator);
Justin Glass, M.D. (coinvestigator); Sara Michaels, M.D.
(coinvestigator); Peter H. Bennett, MB, FRCP (coinvestiga-
tor); Tina Morgan (coinvestigator); Shandiin Begay, MPH;
Bernadita Fallis RN, RHIT, CCS; Jeanette Hermes, MS, RD;
Diane F. Hollowbreast; Ruby Johnson; Maria Meacham,
BSN, RN, CDE; Julie Nelson, RD; Carol Percy, RN; Patricia
Poorthunder; Sandra Sangster; Nancy Scurlock, MSN, ANP-
C, CDE; Leigh A. Shovestull, RD, CDE; Janelia Smiley; Katie
Toledo, MS, LPC; Christina Tomchee, B.A.; Darryl Tonemah
Ph.D.
University of Southern California. Anne Peters, M.D. (prin-
cipal investigator); Valerie Ruelas, MSW, LCSW (program
coordinator); Siran Ghazarian Sengardi, M.D. (program
coordinator); Kathryn Graves, MPH, RD, CDE; Kati Koners-
man, MA, RD, CDE; Sara Serafin-Dokhan.
A.2. Coordinating Center
Wake Forest University. Mark A. Espeland, Ph.D. (principal
investigator); Judy L. Bahnson, B.A. (program coordina-
tor); Lynne Wagenknecht, DrPH (coinvestigator); David
Reboussin, Ph.D. (coinvestigator); W. Jack Rejeski, Ph.D.
(coinvestigator); Alain Bertoni, M.D., MPH (coinvestigator);
Wei Lang, Ph.D. (coinvestigator); Gary Miller, Ph.D. (coin-
vestigator); David Lefkowitz, M.D. (coinvestigator); Patrick
S. Reynolds, M.D. (coinvestigator); Paul Ribisl, Ph.D. (coin-
vestigator); Mara Vitolins, DrPH (coinvestigator); Michael
Booth, MBA (program coordinator); Kathy M. Dotson, B.A.
(Program coordinator); Amelia Hodges, BS (program coor-
dinator); Carrie C. Williams, MA (program coordinator);
Jerry M. Barnes, MA; Patricia A. Feeney, MS; Jason Griffin,
BS; Lea Harvin, BS; William Herman, M.D., MPH; Patricia
Hogan,MS; Sarah Jaramillo, MS;Mark King, BS; Kathy Lane,
BS; Rebecca Neiberg, MS; Andrea Ruggiero, MS; Christian
Speas, BS;Michael P.Walkup,MS; KarenWall, AAS;Michelle
Ward; Delia S. West, Ph.D.; Terri Windham.
A.3. Central Resources Centers
DXAReading Center, University of California at San Francisco.
Michael Nevitt, Ph.D. (principal investigator); Susan Ewing,
MS; Cynthia Hayashi; JasonMaeda, MPH; Lisa Palermo, MS,
MA;Michaela Rahorst; Ann Schwartz, Ph.D.; John Shepherd,
Ph.D.
Central Laboratory, Northwest Lipid Research Laboratories.
Santica M. Marcovina, Ph.D., ScD (principal investigator);
Greg Strylewicz, MS.
ECG Reading Center, EPICARE,Wake Forest University School
of Medicine. Ronald J. Prineas, M.D., Ph.D. (principal inves-
tigator); Teresa Alexander; Lisa Billings; Charles Campbell,
AAS, BS; Sharon Hall; Susan Hensley; Yabing Li, M.D.; Zhu-
Ming Zhang, M.D.
Diet Assessment Center, University of South Carolina, Arnold
School of Public Health, Center for Research in Nutrition
and Health Disparities. Elizabeth J. Mayer-Davis, Ph.D.
(principal investigator); Robert Moran, Ph.D.
Hall-Foushee Communications, Inc. Richard Foushee, Ph.D.;
Nancy J. Hall, MA.
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A.4. Federal Sponsors
National Institute of Diabetes and Digestive and Kidney
Diseases. Barbara Harrison, MS; Van S. Hubbard, M.D.
Ph.D.; Susan Z.Yanovski, M.D.
National Heart, Lung, and Blood Institute. Lawton S. Cooper,
M.D., MPH; Jeffrey Cutler, M.D., MPH; Eva Obarzanek,
Ph.D., MPH, RD.
Centers for Disease Control and Prevention. Edward W.
Gregg, Ph.D.; David F. Williamson, Ph.D.; Ping Zhang, Ph.D.
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